Ken Alltucker is a Health Reporter at USA Today. He focuses on healthcare issues, including the healthcare system, alternative medicine, and medical specialties, while also covering relevant topics such as the FDA, data, and social issues. Ken's work has been featured in notable publications including the Detroit Free Press, Yahoo News, and The Arizona Republic.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ken Alltucker's coverage is heavily focused on health-related topics, particularly healthcare and pharmaceutical issues. He frequently cites data and government announcements to support his articles. To effectively reach out to him, consider providing insights supported by relevant data or offering perspectives on recent government announcements related to healthcare policies or regulations.
Additionally, since Ken focuses on national coverage in the United States, pitches should be tailored with this geographic focus in mind. If you have expertise in healthcare policy, medication pricing, patient rights advocacy or similar fields within the US context, your input could resonate well with his reporting.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Ken Alltucker, USA TODAY · 9 min read For Debbie Halstead, the weight loss medication Wegovy has been nothing short of a miracle.
Ken Alltucker, USA TODAY · 3 min read Researchers have long warned about the harmful effects of lead in paint, pipes and other products.
By: Dea Yancey-Bragg, Santucci, Ken Alltucker
The brazen murder of UnitedHealthcare CEO Brian Thompson has unleashed social media scorn at his company and a U.S. health insurance industry that serves as gatekeeper to the nation's $4.5 trillion health care system.
Decades of leaded gasoline exposure in the United States linked to mental health conditions such as depression, anxiety, ADHD and neurotic behavior.
Anger over the US healthcare system boiled over this week after the NYC killing of an insurance company executive
By: Ken Alltucker
Average life expectancy in the U.S. increased by almost a year in 2023, rebounding to a level not reached since the COVID-19 pandemic, according to figures released Thursday by the Centers for Disease Control and Prevention.
By: Ken Alltucker
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Consumers who take copies of the popular weight loss and diabetes drug tirzepatide will likely need to find a new source for these medications early next year.
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
(833) 317-6278 
